Key result
Selective DOAC drug monitoring improves perioperative safety in high-risk surgical patients.
Why the study?
The perioperative period exposes critical limitations of the paradigm that DOACs have predictable pharmacokinetics requiring no routine monitoring, especially in high-risk populations excluded from landmark trials.
Does selective therapeutic drug monitoring and individualized risk stratification improve perioperative safety compared to a routine 'no monitoring' approach in high-risk patients taking direct oral anticoagulants?
Does selective therapeutic drug monitoring and individualized risk stratification improve perioperative safety compared to a routine 'no monitoring' approach in high-risk patients taking direct oral anticoagulants?
This narrative review provides practical algorithms for perioperative DOAC management, advocating for selective therapeutic drug monitoring and switching to LMWH in complex, high-risk patients where the standard 'no monitoring' paradigm is unsafe.
Answers are grounded in this paper and cite their sources.
May support selective DOAC monitoring and LMWH switch in high-risk perioperative patients; challenges no-monitoring consensus yet leaves open prospective validation.
Direct oral anticoagulants (DOACs) are widely used for thromboprophylaxis in atrial fibrillation and venous thromboembolism. Their marketing emphasizes predictable pharmacokinetics and no need for routine monitoring. However, the perioperative period exposes critical limitations of this paradigm, especially in high‑risk populations excluded from landmark trials. This narrative review integrates hematology and cardiology perspectives. We critically examined real‑world evidence on perioperative DOAC management, focusing on patients with extreme body weight, renal or hepatic impairment, active malignancy, thrombocytopenia, bariatric surgery, and drug–drug interactions. Guideline recommendations and commercial influences were analyzed. Routine therapeutic drug monitoring (TDM) is unnecessary for low‑risk elective procedures in standard patients. However, selective TDM is essential in high‑risk populations where DOAC pharmacokinetics are unpredictable. We identified specific indications for TDM (extreme body weight, CrCl<50 mL/min, Child‑Pugh B cirrhosis, bariatric surgery, interacting drugs) and provided practical algorithms for elective, urgent and emergency surgery. Low‑Molecular‑Weight heparin (LMWH) is preferred when DOAC pharmacokinetics are unpredictable, including malabsorption syndromes, severe thrombocytopenia, and advanced liver disease. Marketing influences have perpetuated the “no monitoring” dogma despite accumulating evidence of harm in vulnerable subgroups. A one‑size‑fits‑all approach to perioperative anticoagulation is unsafe in complex patients. Selective TDM improves safety in high‑risk scenarios. LMWH remains a preferred alternative when DOAC pharmacokinetics are unpredictable. Clinicians should recognise marketing influences and adopt evidence‑based, individualised strategies. Peer Review History: Received 25 July 2026; Reviewed 11 September 2026; Accepted 9 October; Available online 15 November 2026 Academic Editor: Dr. Essam Mohamed Eissa, Beni-Suef University, Egypt, dressamceutics@yahoo.com Reviewers: Dr. Taiwo O Elufioye, University of Ibadan, Nigeria, toonitaiwo@yahoo.com Dr. Showkat Ahmad Bhawani, UNIMAS Sarawak, Malaysia, sabhawani@gmail.com
No takes yet. Share an insight, caveat, or question.
Obeagu et al. (2026) conducted a review in Atrial fibrillation and venous thromboembolism requiring perioperative anticoagulation. Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) with selective therapeutic drug monitoring (TDM) vs. Routine 'no monitoring' paradigm or transition to low-molecular-weight heparin (LMWH) was evaluated on Perioperative safety, bleeding and thrombotic risks, and residual DOAC plasma concentrations (<30 ng/mL, 30-100 ng/mL, >100 ng/mL). Selective therapeutic drug monitoring of DOACs and switching to LMWH improve perioperative safety in high-risk patients with unpredictable pharmacokinetics.
Synapse has enriched 10 related papers. Consider them for comparative context: